The literature has seen an incredible booming of publications related to the use of recombinant adenoviruses as therapeutic tools for lymphoproliferative disorders over the last decade. Several approaches of adenovirus-mediated gene expression have been used to transfect cell lines that are derived from lymphoid tumors and would have otherwise been refractory to other transfection methods. The identification of high-affinity receptor for human adenoviruses serotype 2 and 5, the coxsackie-adenovirus receptor (CAR), has raised the question about its relevance for the efficacy of recombinant adenovirus-mediated gene therapy. We review published studies that have analyzed the use of recombinant adenovirus vectors expressing cytotoxic genes for gene therapy in lymphomas, chronic lymphocytic leukemia and multiple myeloma. For simplicity, we group all these diseases under the term lymphoproliferative disorders. We analyze the use of recombinant adenovirus-mediated cytotoxicity by assessing the importance of the biochemical and intrinsic signaling pathways interacting with the products of the exogenous viral-mediated expression. Ultimately, we discuss studies that have been finalized to by-pass the limitations of the biodistribution of CAR by modifying or targeting adenovirus to other membrane proteins in cells derived from lymphoproliferative disorders.
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Adenovirus-mediated gene therapy for lymphoproliferative disorders
Malignancies derived from the lymphoid system are a unique group of disorders that represent in terms of biology a grading of the phenotype-arrest during the natural process of maturation and differentiation of the lymphoid cells. 1 The complexity of the malignant process involving the cells of the lymphoid system such as T, B, Null cells or plasmacell is illustrated by the diversity of diseases like lymphomas, acute and chronic lymphocytic leukemias (ALL and CLL) and multiple myeloma (MM). For simplicity, we will group these malignancies under one category named lymphoproliferative disorders, though they represent separate entities that undergo different treatment.
Our interest derives from the increasing number of publications that have been dealing with the potential use of gene therapy for lymphoproliferative disorders in the last decade. The identification of a high-affinity receptor for human adenoviruses serotype 2 (Ad2) and 5 (Ad5), the coxsackie-adenovirus receptor (CAR), has raised the question whether the presence of the receptor on target cells is important or not for the efficacy of recombinant adenovirus-mediated gene therapy. 2, 3 For the purpose of this review, we will therefore analyze published studies that have examined the use of recombinant adenovirus vectors expressing cytotoxic genes for gene therapy in lymphomas, CLL and MM. Nevertheless, in the current review we will not consider the published literature related to the use of recombinant adenovirus-mediated expression of proteins that are involved in immunomodulation of tumor response in lymphoproliferative disorders. This matter has been addressed in several reviews that have recently been published. 4, 5 Recombinant adenovirus-mediated cytotoxic gene therapy
Cancer is the endpoint of an accumulation of multiple genetic mutations that results in cellular phenotype characterized by uncontrolled growth. The ultimate goal of cancer therapy is to kill tumor cells by inducing cytotoxicity. This concept has made virus-mediated gene therapy an ideal candidate for therapeutic strategies either in alternative or complementary to chemotherapy or radiotherapy. The success of effective virus-mediated gene therapy of cancer faces major pitfalls such as in vivo targeting and effective transduction of each tumor cell. Despite these limitations, the direct-virus-mediated cytotoxic therapy and the virus-based-cytotoxic gene transfer are two valid modalities that deserve further consideration. Although the second-generation and helper-dependent adenovirus vectors have improved the long-term gene expression, the first-generation adenoviral vectors remain a potential valid therapeutic tool in cancer therapy, where a short-term expression in cells, that would have otherwise been refractory to traditional transfection methods, is the major requirement. 6 Modalities of recombinant adenovirusmediated cytotoxic gene therapy in lymphoproliferative disorders
The recombinant adenovirus-mediated expression of prodrug enzyme is one of the strategies that has been used to induce cytotoxicity in cells derived from lymphoproliferative disorders. 7, 8 In one study, cells derived from anaplastic large cell lymphoma (ALCL), Hodgkin's disease (HD), B-non-Hodgkin's lymphoma (B-NHL) and MM exhibited efficient in vitro killing by the combination of adenovirus-mediated herpes simplex virus thymidine kinase (HSV-tk) expression and the drug ganciclovir (GCV). 7 In another study, the same modality of killing was used as an ex vivo model of purging of cells derived from MM. 8 In this study, the tumor-selective promoter DF3/MUC1 was used to guarantee selectivity of infection of MM-derived cells (MUC1-positive) compared with hematopoietic progenitor cells (MUC1-negative). 8 The protein p53 is the most frequent mutated tumor suppressor gene that is present in human cancer. 9 The lack of function by p53 is ultimately responsible for tumor progression and for resistance of tumor cells to chemotherapy or radiation therapy. 10 The replacement of a mutated p53 with a functional p53 is the rationale behind this gene therapy approach. The exogenous expression of the p53 protein triggers apoptosis in cells that would have been otherwise resistant to the mechanism of death. Recently, recombinant adenovirusmediated expression of wild-type p53 has been extensively studied in cancer. 11 More recently, the use of firstgeneration recombinant adenovirus-mediated expression of p53 in cells derived from lymphoproliferative disorders has been extensively explored by our group. 7, 12 For the first time, we showed efficacy of recombinant adenovirus-p53-mediated cytotoxicity in vitro in cells derived from t(2;5)-ALCL, HD Burkitt's lymphoma and MM. 7 Ultimately, we correlated the transduction and killing of SUDHL-1 cells derived from t(2-5)-ALCL with the expression of CAR and a n b integrins. 12 Although SUDHL-1 cells presented an endogenous expression of p53, only the adenovirus-mediated expression of wildtype p53 triggered apoptosis in SUDHL-1 cells by inducing higher levels of p21 waf1 . 12 This finding was consistent with a non-functional p53 pathway in SUDHL-1 cells, whose abnormality remains unknown. 12 We subsequently showed the efficacy of adenovirus-p53-mediated gene therapy of xenograft-tumor derived from SUDHL-1 cells in a nude mouse model. 13 Other investigators have correlated the level of apoptosis induced by adenovirus-mediated expression of p53 with the presence of p53 mutants in cells derived from Blymphoma. 14 The same cells transfected to express wildtype p53 showed increased sensitivity to cytotoxic drug and immuno-mediated toxicity.
14 Finally the efficacy of adenovirus-p53-mediated apoptosis has been inversely correlated with the level of expression of bcl-2 in cells derived from MM. 15 The same group of investigators has shown an additive effect of Apo2 ligand or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) and recombinant adenovirus-mediated p53 expression in terms of level of apoptosis observed in cells derived from MM. 16 It has recently been shown that recombinant adenovirus-mediated expression of cyclin-dependent kinase inhibitors (CDKIs) induces cell cycle arrest and apoptosis in cells from epithelial-derived tumors. [17] [18] [19] For the first time, we showed that adenovirus-mediated p27 Kip1 expression was able to induce in vitro apoptosis in SUDHL-1 cells derived from t(2:5)-ALCL. 20 , 21 We also demonstrated that the effects of adenovirus-mediated p27
Kip1 expression were cell dependent and differed from the effects of adenovirus-mediated p53 expression in SUDHL-1 cells. 20, 21 Finally, we have recently shown that adenovirus-mediated expression of p27 Kip1 , p21
Waf1 or p16 INK4A induced apoptosis in cells derived from ALCL in the order of efficacy Adp274Adp21 @ Adp16. 22 On the contrary, cells derived from HD were resistant to apoptosis induced by the same recombinant adenoviruses. 22 The difference in the level of apoptosis was correlated with the level of phosphorylation of the retinoblastoma (Rb) protein in the cell lines tested. 22 More recently, other investigators have explored the use of adenovirus-mediated cytotoxic gene therapy with an approach different from those previously discussed. 23, 24 The inhibition of the nuclear factor k B (NFkB) by adenovirus-mediated expression of dominant negative inhibitor k Ba (Ad5IkB) caused apoptosis in U266 cells, derived from MM. 23 In another study, the same results were obtained with the same Ad5IkB in cell derived from HD. 24 Ultimately, some gene products derived from the adenovirus genome may induce apoptosis as it has been recently reviewed. 25 In recent years, several investigators have considered to modify the genetics of adenovirus particles to create mutants of the E1A or E1B region of the viral genome that complement the host proteins involved in the regulation of the cell cycle or apoptosis. [26] [27] [28] [29] The use of attenuated mutant adenoviruses has been explored ex vivo in cells derived from patients with CLL in a recent study. 30 Although the mechanism of cytotoxicity induced by recombinant adenovirus mutants was not elucidated, the investigators showed that adenovirus mutant lacking E1A (E1AÀ), adenovirus mutant lacking E1B (Ad5dl337) and adenovirus mutant lacking both E1A and E1B (Pac3) presented cytotoxic effects that varied among different recombinant viruses and cells derived from different patients. 30 Despite the limitations of the study, it remains the only example in the literature that evaluates the effects of direct adenovirus cytotoxicity in cells derived from lymphoproliferative disorders.
Analysis of the relevance of CAR, gene product and the biochemical cellular pathways for the efficacy of adenovirusmediated cytotoxic gene therapy in lymphoproliferative disorders: a perspective in terms of pharmacodynamics
The knot of the coat fiber protein of the adenovirus primarily binds to cells through CAR. 31 The attachment of the fiber to CAR brings the viral particle closer to the Gene therapy of lymphoproliferative disorders F Turturro surface of the cell membrane allowing a secondary binding of the coat penton base to the a n b 3 or a n b 5 integrins. In some cell types, the penton base-integrin interaction triggers the virus internalization by endocytosis of coated pits containing viral particles. 32, 33 It has also been reported that the fiber protein can in addition interact with the a2-domain of the human major histocompatibility complex (MHC) class I. 34, 35 It is widely accepted that CAR represents the highaffinity receptor for Ad2 and Ad5 and other adenovirus serotypes. 36 In fact, a recent study showed that the ectopic expression of CAR in murine lymphoid-derived cell lines that were resistant to adenovirus infection was sufficient to notably increase the transduction of the same cells by recombinant adenoviruses. 37 Furthermore, the relevance of CAR as a primary receptor for adenoviruses has recently been illustrated in several transgenic mouse models. [38] [39] [40] In initial studies, it was shown by two different groups how the transgenic expression of CAR enhanced the infection and transduction of naïve T cells and primary lymphocytes, respectively. 38, 39 In a more recent study, a transgenic mouse has been engineered to express a functional truncated CAR in all tissues of the animal. 40 This model clearly indicates that the limited expression of CAR observed in several species (eg human species included) influences susceptibility to adenoviruses more than that of the ubiquitous integrins. 40 Moreover, the study also shows that a uniform tissue expression of CAR in the animal completely changes the biodistribution and the pharmacokinetics of the adenovirus particle. 40 The findings of this recent study confirm our observation and that by other investigators on the correlation between the efficiency of adenovirus infection and the expression of CAR in cells derived from lymphoproliferative disorders. 8, 12, 14, 22 Nevertheless, the issue remains controversial as shown by a recent study. 41 Einfeld et al showed that the modification of the native tropism of adenovirus particles required disruption of both CAR and a n integrin interaction, by using vectors that were lacking CAR binding, a n integrin binding or both. 41 In the same species, the expression pattern of CAR varies during embryogenesis and in different tissues. Other investigators and we have shown that cells derived from lymphoproliferative malignancies express CAR, whereas their normal counterparts lack the expression of the same protein. 8, 12 We have previously hypothesized that the expression of CAR may have been part of the malignant phenotype of ALCL as compared to normal lymphoid cell. 12 We also hypothesized that the concurrent expression of CAR and integrins may have represented a lymphoid-epithelial transformation of the cell originating ALCL that explains the propensity of this lymphoma to metastasize to soft tissues. 12 Recent observations that present CAR as adhesion molecule seem to validate our hypothesis. 42 If we compare the adenovirus particle to a drug, and CAR and a n b integrins to its receptor and co-receptors, we may represent their interaction in a pharmacodynamics model. In this model, the consequences of the drug-receptor interaction depend on the specific biochemical pathways of the host cell that are solicited by the product of the cytotoxic gene carried by the recombinant adenovirus vector and by the dose/multiplicity of infection (moi) of the vector itself. In fact, other investigators and we have recently elucidated this concept in studies that will be discussed. 12, 15, [20] [21] [22] In one study, we showed that the recombinant adenovirusmediated expression of exogenous p27
Kip1 was equally efficient in the cytoplasm and in the nucleus of SUDHL-1 and KARPAS 299 cells derived from t(2;5)-ALCL. 20 The presence of CAR and integrins on the cell surface of SUDHL-1 (Ref. 12) and KARPAS 299 cells (unpublished data) and the efficiency of the CMV promoter allowed the recombinant adenovirus Adp27 to express the cytotoxic gene. 20 When we assessed the consequences of the expression of p27
Kip1 on the life of the two cell lines, there were differences in response between the two cell lines tested. Biochemical differences in the signaling pathways between the two cell lines were responsible for the different response to the same recombinant adenovirus. 20 In another study, biochemical differences between SUDHL-1 and L428 cells that were derived from ALCL and HD, respectively, were also found to correlate with differences in response to the cytotoxic effect of recombinant adenovirus-mediated expression of CDKIs. 22 CAR was equally expressed on the cell surface of both cell lines tested. 22 Other investigators found that the level of apoptosis in response to adenovirusmediated expression of p53 was correlated with biochemical differences in MM-derived cells. 15 Furthermore, we recently showed that the level of apoptosis and the chronology of the event are correlated with the type of cytotoxic gene that is expressed by the recombinant adenovirus in the same cell line. 21 In fact, we analyzed the differences in cell cycle and apoptosis induced by the recombinant adenovirus-mediated expression of p53 or p27
Kip1 in SUDHL-1 cells. 21 The cytotoxic effect of the recombinant-mediated expression of p27
Kip1 was moi-dependent and it varied from cytostasis (prolonged G1 arrest of the cell cycle) at lower moi to frank apoptosis at higher moi of adenovirus. 21 The dose-dependent dual effect of cytostasis/apoptois has been confirmed in a recent study, where we analyzed the effects of recombinant adenoviruses-mediated expression of p27 Kip1 , p21 WAF1 or p16 INK4A in SUDHL-1 cells. 22 The past, the present and the future: infectivity of the lymphoid-derived cells and targeting the virion
In the pre-CAR era of adenovirus-mediated gene therapy of lymphoproliferative disorders, there have been several studies addressing the infectivity of in vitro or in fresh isolates of tissues from patients with such disorders. 7, 28, [43] [44] [45] These initial studies were discouraging for the low infectivity shown by the cells and fresh tissue tested. [43] [44] [45] In one study, high moi of adenoviral particles were necessary to infect cells derived from CLL. 28 In recent years, other investigators and we have shown that the expression of CAR that was detected by flow cytometry analysis of cells stained with monoclonal antibody anti-CAR, RmcB, varies among cells derived from several lymphoproliferative malignancies as compared with normal cell counterparts. 8, 12 More recently, there has been an increase of studies that have been finalized to by-pass the limitations of the biodistribution of CAR in tissues by targeting adenovirus to other Gene therapy of lymphoproliferative disorders F Turturro membrane proteins. 46 For the purpose of this review, we will discuss only studies that have investigated the targeting of adenovirus in cells derived from lymphoproliferative disorders. A group of investigators have shown that modified recombinant adenovirus AdZ.F(pK7), through polylysine-binding to heparansulfate-containing receptors, was able to increase virus absorption and gene transfer efficiency in MM-derived cells that express such receptors. 47 In another study, adenovirus particles equipped with a chimeric fiber bearing the receptor-binding knob domain of the Ad3 were more effective than Ad5-wild-type fiber particles in transducing Epstein-Barr virus (EBV)-transformed B lymphocytes, which are traditionally resistant to adenovirus infection. 48 Lastly, the use of CD70-fiber bispecific antibody enhanced adenovirus infection of CD-70-positive cells derived from B-lymphoproliferative disorders. 49 The modified recombinant adenoviruses that were used in all the mentioned studies were engineered to express reporter genes such as b-galactosidase and GFP. [46] [47] [48] [49] Unfortunately, these proteins lack any 'therapeutic' cytotoxic activity. For this reason, we cannot establish from the conclusions of these studies whether or not the effort of improving the pharmacodynamics of adenovirus/drug in cells resistant to Ad will translate in therapeutic efficacy.
Conclusion
In conclusion, we may cautiously state that the idea of using recombinant adenovirus-mediated cytotoxic therapy for lymphoproliferative disorders is feasible based on results obtained in vitro, ex vivo and in vivo in an animal model. The importance of CAR expression, the relevance of the cellular signaling pathways and the biochemical differences have been underlined in our effort to understand what has been already published in this context. We hope that this effort will help in defining issues that require further consideration, in an attempt to translate the accomplishments to the clinical level.
